Back to results
US 9,175,345 B2Granted
Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
AssigneeAccera, Inc.
InventorSamuel T. Henderson
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease.
Claims6
A method of treatment for Alzheimer's disease, comprising the steps of:
- a. selecting a human patient having, or at risk of Alzheimer's disease;
- b. determining in the patient the presence of at least one of the specific genotypes selected from the group consisting of:
- i. heterozygosity for C/T for Insulin Degrading Enzyme (IDE) rs 2251101 at relevant portion shown by SEQ ID NO:3, and
- ii. absence of homozygosity for C/C of IDE rs 2251101 at relevant portion shown by SEQ ID NO:3;
- and
- administering to the patient having at least one of the specific genotypes in (b a composition comprising an effective amount of medium chain triglycerides (MCT) of the formula:
- wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbon chains.
4 more elements
Dependencies are inferred from the claim text.